Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
KAZAKHSTAN:in prospect                   April 2011
Kazakhstan Pharmaceutical MarketThe access to the pharmaceutical marketplace of any region is always paired with risks,cha...
Kazakhstan:in prospect                                                                                                    ...
SMD (Support in Market Development) - is a leading provider of market research,sales management and forecasting services t...
Upcoming SlideShare
Loading in …5
×

Kazakhstan pharmaceutical market 2010

1,928 views

Published on

Kazakhstan pharmaceutical market 2010

Published in: Health & Medicine, Business
  • Be the first to like this

Kazakhstan pharmaceutical market 2010

  1. 1. KAZAKHSTAN:in prospect April 2011
  2. 2. Kazakhstan Pharmaceutical MarketThe access to the pharmaceutical marketplace of any region is always paired with risks,challenges and political, financial and economical factors specific to each region.Kazakhstan is situated in central Asia, northwest of China; with a small portion alcohol and tobacco use and suicide rates. Additionally, Kazakhstan is facing awest of the Ural River in the easternmost part of Europe. It is the world’s largest number of environmental challenges, including industrial pollution, landlandlocked country. It is also the ninth largest country in the world. degradation, desertification, the nuclear heritage of the Semipalatinsk polygonThe main activities of the Ministry of Health consist of implementing the and the negative influence of urbanization on public heath. Such zoonoticnational programme of health sector reform and development for 2005–2010 diseases as Crimean-Congo hemorrhagic fever, anthrax, brucellosis, plague andwith the focus on: tularemia are still endemic in the country.1. reforms and development of the health delivery system (primary health Maternal and infant mortality remain high and the Ministry of Health has care, sanitary epidemiological services, and health promotion); declared its decrease to be its number one priority. Analysis shows that over half of infant mortality and a third of maternal mortality are the result of poor quality2. improvement of the health management system; maternal and child health services and can be averted. Too much emphasis has3. maternal and child health; been placed on high technology projects and activities, with heavy investments4. training and re-training of health personnel (reform of medical and in new equipment and infrastructure over the last few years. Relatively little pharmaceutical education); and attention is paid to the quality of maternal and child health services and the5. the government programme “100 schools, 100 hospitals”, supervising the strengthening of basic public health measures. The infant mortality rate was construction and launch of 100 hospitals in regions with high demand in 14.43 per 1000 live births in 2007 which is high compared with regional data. new health facilities. Maternal mortality levels remain much higher than the European averages, being registered in 2007 is 47.52 per 100 000 live births.The Ministry of Health is also partly responsible for the construction of newpharmaceutical factories, which should cover the national demand for drugs in Child immunization levels have been consistently high in Kazakhstan for allthe framework of the newly launched government programme “30 vaccine-preventable diseases. In 2008, 100% and in 2009, 99.3% of children weremanufacturing leaders of Kazakhstan”. Both programmes are coordinated and immunized against measles. Sexually transmitted infections sharply increasedfunded by the Fund for Sustainable Development “Samruk-Kazyna”. after independence, with syphilis incidence in 2007 reaching 45.9 per 100 000 population. The incidence of tuberculosis is 160.01 per 100 000 population.The Ministry of Health reorganized the structure of its departments andcommittees twice during 2008–2009.Kazakhstan faces high maternal, infant and under-5 mortality rates, high Kazakhstan:in prospect is availablemorbidity from diseases of the cardiovascular system and mental health,unhealthy lifestyles and in particular drug abuse and tobacco/alcohol use, high at Euros 160.00morbidity from communicable diseases (such as tuberculosis, HIV/AIDS and To know more about our report or to discuss this topic furthersexually transmitted diseases), nosocomial infections (such as hepatitis and please do not hesitate to contact usHIV/AIDS through unsafe blood transfusion). Other characteristics are pooraccess to essential services, especially in rural places and through the old Tel/Fax: +38 044 206 17 17/18managerial capacity of health service delivery institutions, and rather high e-mail: office@smd.net.ua
  3. 3. Kazakhstan:in prospect EECCA: Region Features Economic Development Pharmaceutical Market: Executive Summary Pharmaceutical Market: Main Features Pharmaceutical Market: Structure Kazakhstan Country profile Investment climate Healthcare system features Healthcare system funding Kazakhstan: Pharma Market Key data Main features Guaranteed Volume of free Medical Aid (GFMA) structure Hospitals supply through the national distributor Retail market and state procurement ATC 1 dynamics. Retail total, USD ATC 1 dynamics. Retail total, Units ATC 1 dynamics. Rx segment, USD ATC 1 dynamics. Rx segment, Units ATC 1 dynamics. OTC segment, USD ATC 1 dynamics. OTC segment, Units Leading corporations. Retail total, USD Leading corporations. Retail total, UnitsDISCLAIMER Leading corporations. Rx segment, USDAll information contained in this publication Leading corporations. Rx segment, Unitshas been researched and compiled from sources Leading corporations. OTC segment, USDbelieved to be accurate and reliable at the timeof publishing. However, SMD accepts no Leading corporations. OTC segment, Unitsliability whatsoever for any loss or damage Leading local manufacturers. Retail total, USDresulting from errors, inaccuracies or omissions Leading local manufacturers. Retail total, Unitsaffecting any part of the publication. Allinformation is provided without warranty, and Import by countries of originSMD makes no representation of warranty of Kazakhstan: Forecast for 2011-2013any kind as to the accuracy or completeness of Retail Segment, USDany information hereto contained. Addendum 2-phased opened tender procedures. 1st phaseKazakhstan:in prospect 2-phased opened tender procedures. 2nd phase© 2011 SMDAll information contained in this publication is copyrighted in the name of SMD (Support in Market Development), and as such no part ofthis publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any meansgraphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means,without the express written consent of the publisher.
  4. 4. SMD (Support in Market Development) - is a leading provider of market research,sales management and forecasting services to the pharmaceutical industry.Researches of:· Pharmaceutics establishments purchase and sale audit· Hospital establishments purchase audit· Second distribution audit Ukraine, 03680· Import medicine analyses Bojenko str., 86i, Kiev· Doctor prescription analyses Tel/Fax: +38 044 206 17 17/18· Ad Hoc research e-mail: office@smd.net.ua· Analytical services http://www.smd.net.ua Kazakhstan:in prospect April 2011

×